PF-AtlasClinical Trials › NCT05318599

Deep Learning Diagnostic and Risk-stratification for IPF and COPD

Lung auscultation · Not specified

Registry ID
NCT05318599
Phase
Not specified
Status
Unknown
Drug / intervention
Lung auscultation
Sponsor
Pediatric Clinical Research Platform
Start
2023-04-01
Enrollment
160
Locations
1

About this trial

Idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and chronic obstructive pulmonary disease (COPD) are severe, progressive, irreversibly incapacitating pulmonary disorders with modest response to therapeutic interventions and poor prognosis. Prompt and accurate diagnosis is important to enable patients to receive appropriate care at the earliest possible stage to delay disease progression and prolong survival. Artificial intelligence (AI)-assisted digital lung auscultation could constitute an alternative to conventional subjective operator-related auscultation to accurately and earlier diagnose these diseases. Moreover, lung ultrasound (LUS), a relevant gold standard for lung pathology, could also benefit from automation by deep learning.

View NCT05318599 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT05318599 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.